Skip to main content
. Author manuscript; available in PMC: 2013 Mar 28.
Published in final edited form as: Pigment Cell Melanoma Res. 2009 May 28;22(4):400–419. doi: 10.1111/j.1755-148X.2009.00585.x

Figure 10. Targeting Akt3 and V600EB-Raf synergistically inhibits melanoma tumor development.

Figure 10

SiRNAs targeting Akt3 (100 picomoles) and V600EB-Raf (12.5 picomoles) were introduced into UACC 903 melanoma cells alone or in combination, which were injected subcutaneously in to mice and tumor development measured on alternate days upto days 17.5. Compared to controls (buffer, siScrambled or siC-Raf) an ~60% reduction in tumor development was observed targeting Akt3 or V600EB-Raf alone. A much more dramatic reduction (~80%) was when these proteins were targeted together. Inset shows decreased Akt3 and V600EB-Raf protein expression levels in melanoma tumors at days 9.5 (Cheung et al., 2008).